Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979024 | 0.88 | CYP3A4 (0.45) | KDM5BALDH1A1POLBTSHRMAPK1 | |
| SCHEMBL5128656 | 0.84 | USP2 (0.61) | ALDH1A1TSHRSMN1; SMN2EPHX2TDP1 | |
| SCHEMBL4981629 | 0.80 | DRD4 (0.44) | ALDH1A1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL4220447 | 0.79 | USP2 (0.67) | ALDH1A1POLBMAPK1TDP1L3MBTL1 | |
| SCHEMBL14263114 | 0.79 | DRD4 (0.73) | POLBSMN1; SMN2EPHX2 | |
| SCHEMBL10210809 | 0.78 | KDM5B (0.55) | KDM5BALDH1A1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL4981056 | 0.77 | ALDH1A1 (0.55) | ALDH1A1POLBTSHRSMN1; SMN2 | |
| SCHEMBL4981471 | 0.76 | ALDH1A1 (0.64) | ALDH1A1EPHX2TDP1 | |
| SCHEMBL4982809 | 0.76 | DRD4 (0.49) | ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL5465155 | 0.76 | KMT2A (0.57) | ALDH1A1POLBTSHRSMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | KDM5B 796/4885ALDH1A1 451/4885POLB 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.